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Prognostic Usefulness of Cardiopulmonary Exercise
Testing for Managing Patients With Severe
Aortic Stenosis
Van D. Le, PhD, Gunnar V. Jensen, PhD, and Lars Kjøller-Hansen, DMSc*
The approach to managing asymptomatic or questionably symptomatic patients for aortic
stenosis is difficult. We aimed to determine whether cardiopulmonary exercise testing (CPET)
is prognostically useful in such patients. Patients judged asymptomatic or questionably symp-
tomatic for aortic stenosis with aortic valve area index <0.6 cm2/m2 and left ventricular ejection
fraction ≥0.50 were managed conservatively provided they had either (group 1) normal peak
oxygen consumption and peak oxygen pulse (>83% and >95% of the predicted values, re-
spectively) or (group 2) subnormal peak oxygen consumption or peak oxygen pulse but with
CPET data pointing to pathologies other than hemodynamic compromise from aortic ste-
nosis. Increase in systolic blood pressure <20 mm Hg, ST depression ≥2 mm, or symptoms
during the exercise test were allowed. Unexpected events included cardiac death or hospi-
talization with heart failure in patients who had not been recommended valve replacement.
The median age of the study population (n = 101) was 75 years (interquartile range 65 to
79 years), and 67% were judged questionably symptomatic. During a follow-up at 24 ± 6
months, the rate of unexpected cardiac death and unexpected hospitalization with heart
failure was 0% and 6.0%, respectively. All-cause mortality was 4.0% compared with 8.0%
in the age- and gender-matched population. For group 1, 26 of 70 (37.1%) succumbed to
cardiac death, or were hospitalized because of heart failure, or underwent valve replace-
ment, and for group 2 this was 12 of 31 (38.7%). In conclusion, if CPET does not indicate
a significant hemodynamic compromise because of aortic stenosis, an initially conserva-
tive strategy results in a good prognosis and an acceptable event rate. © 2017 The Author(s).
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2017;120:844–849)
For patients who are asymptomatic or questionably symp-
tomatic for aortic stenosis, it is often difficult to determine
whether or not the patient has significant hemodynamic com-
promise resulting from the aortic stenosis. In particular,
this diagnosis is difficult for patients aged >70 years, for
those who are classified as functional class II, and for pa-
tients with co-morbidities or a sedentary lifestyle.1,2 Field
exercise testing is often used,3 but this is of limited value in
such patients.1,2 In contrast to field exercise testing, cardio-
pulmonary exercise testing (CPET) is a laboratory test that
assays cardiopulmonary physiology during exercise in greater
detail.4 Aortic valve replacement (AVR) is not without risks
or complications,5 and patients are often reluctant to undergo
this operation, causing them to postpone AVR. It is valu-
able for physicians and patients to possess knowledge
about which parameters predict a safe initial deferral. We hy-
pothesized that for patients judged to be asymptomatic or
equivocally or mildly symptomatic for severe aortic steno-
sis by a cardiologist, an initial conservative treatment strategy
could yield a good prognosis and acceptable event-rate after
stratification by a CPET. This includes patients aged >70 years,
with New York Heart Association II classification or an ab-
normal field exercise test.
Methods
Our primary aim was to demonstrate that if peak oxygen
consumption (VO2) and peak oxygen pulse (O2pulse) were
either (1) not subnormal or (2) subnormal, but CPET results
pointed to major causes other than hemodynamic compro-
mise from the aortic stenosis, the following end points would
occur with a low and acceptable incidence.
A. Unexpected cardiac death or hospitalization with heart
failure. Defined as a cardiac death or hospitalization with
heart failure in a patient that had not been recommended
AVR earlier in the study period.
B. Cardiac death, hospitalization with heart failure, or pro-
gression to AVR.
C. All-cause mortality. All-cause mortality was compared
with the age- and gender-matched mortality in our
region (similar distribution of gender and age groups
in 5-year intervals), which can be calculated from
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Patients were recruited from our outpatient clinic. Inclu-
sion criteria were as follows: asymptomatic, equivocally, or
mildly symptomatic status from aortic stenosis as judged by
a cardiologist, aortic valve area index <0.6 cm2/m2, and left
ventricular ejection fraction ≥0.50. Exclusion criteria were
as follows: more than trivial other valvular disease, atrial fi-
brillation with a resting heart rate >90 beats/min, inability to
perform bicycle exercise test, and other known medical con-
ditions or abuse that could result in survival rate <2 years.
All included patients provided written informed consent,
and the study was approved by the local ethics committee
(1-01-83-0002-07).
Based on the outcomes and evaluations of the baseline
CPET, the patients were prospectively categorized. Patients
in whom peak VO2 and peak O2pulse were either not sub-
normal (group 1) or subnormal, but CPET results pointed to
major causes other than hemodynamic compromise from aortic
stenosis (group2), followed an initial conservative strategy.
Predefined criteria for group 1 and group 2 are presented under
Table 1. Patients with subnormal peak VO2 and peak O2pulse
not explainable by causes other than hemodynamic compro-
mise from aortic stenosis were referred for AVR. These patients
were not included in the present study.
The study patients were followed with clinical evalua-
tions at 3 months’ intervals. Echocardiography and CPET were
performed at 6 and 12 months’ intervals, respectively. If a
patient presented new or worsening symptoms, or if he or
she described decreasing functional capacity, a CPET and an
echocardiogram were recommended. The patient was also re-
ferred for a coronary angiogram, and a decision regarding AVR
was made by an independent Heart Team (nonstudy physi-
cians), who did not possess knowledge of the details of the
CPET. Nine months post-AVR an echocardiography and a
CPET were recommended. Vital status, hospitalizations, and
AVR data were obtained on December 1, 2012 from the
Danish National Patient Registry, hospital records, and in-
formation obtained during the study. The cause of death was
determined from the primary diagnosis in the discharge
summary.
CPET was performed on a bicycle ergometer with breath-
by-breath measurement of the VO2, carbon dioxide exhaustion
(VCO2), and minute ventilation (VE) (Innocor, Innovision
version 6.15, Odense, Denmark) as previously described.7
The key measurements obtained from CPET were peak VO2
(expressing cardiac output), peak O2pulse (expressing stroke
volume), VE/VCO2 at nadir (a higher value indicates a
ventilatory/flow mismatch), and the respiratory coefficient
(R = VCO2/VO2, where a value at peak exercise <1 points to
inadequate effort or nonphysiological hyperventilation). An
estimate of stroke volume (milliliter) at peak exercise
was obtained from the following calculation (peak
O2pulse/hemoglobin in g/dL) × 100; O2pulse/hemoglobin
index). This was because hemoglobin in gram per deciliter
corresponds to the milliliter of oxygen extraction per deciliter.8,9
The predicted peak VO2 was defined according to current
recommendations.10 A peak VO2 <83% of the predicted value,
which represents the lower 95% confidence value in a healthy
sedentary population,9,11 was regarded as abnormal. The pre-
dicted peak heart rate was calculated as 220 minus the patient’s
age. The predicted peak O2 pulse was calculated as the pre-
dicted peak VO2/predicted peak heart rate.9 A peak O2 pulse
of <95% of the expected was regarded as abnormal.7 An inert
gas breathing test was performed as previously described.7
All patients underwent 2-dimensional and Doppler
echocardiography as previously described.7 Lateral E/e′ was
calculated as an expression of diastolic pressure. Left ven-
tricular systolic function was assessed using the peak systolic
tissue velocity (Sa) obtained by color tissue Doppler.12 The
mean of the septal and lateral Sa values was used.
For economic and logistical reasons, different assays for
brain natriuretic peptide were used during the study period.
Table 1
Baseline characteristics in the two groups
Group 1 Group 2
(n = 70) (n = 31)
Age (years) 73 ± 10 72 ± 7
Male/female (n) 38/32 23/8
Hypertension 36 (52%) 25 (80%)*
Diabetes mellitus 9 (13%) 3 (10%)
Prior ischemic heart disease 3 (4%) 6 (19%)
Chronic obstructive lung disease 4 (6%) 13 (42%)†
Smoker 9 (13%) 9 (29%)
Atrial fibrillation 2 (3%) 9 (29%)†
Pacemaker 2 (3%) 1 (3%)
NYHA class ≥ II 24 (34%) 21 (68%)*
Equivocally/mildly symptomatic 41 (59%) 26 (84%)*
Body mass index (kg/m2) 27 ± 4 28 ± 5
Body surface area m2 1.9 ± 0.2 2.0 ± 0.2
Creatinine (µmol/L) 80 ± 20 88 ± 23
LDL-cholesterol (mmol/L) 3.1 ± 1.0 2.8 ± 0.9
LDL-cholesterol (mg/dl) 120 ± 39 108 ± 35
Hemoglobin (mmol/L) 8.8 ± 0.6 8.7 ± 0.9
Brain natriuretic peptide > upper level
of normal
11 (17%) 12 (39%)
Resting systolic blood pressure (mm Hg) 133 ± 14 133 ± 19
Echocardiography
Aortic valve area index (cm2/m2) 0.43 ± 0.09 0.46 ± 0.08
Mean gradient (mm Hg) 42 ± 15 33 ± 11*
Left ventricular ejection fraction 59 ± 4 57 ± 5
Sa (cm/s) 5.1 ± 1.2 4.9 ± 1.2
E/e′ 13.5 ± 5.0 13.7 ± 5.3
Left ventricular posterior wall thickness (cm) 1.13 ± 0.22 1.16 ± 0.30
Cardiovascular drugs
Beta blockers 14 (20%) 15 (48%)*
Digoxin 3 (4%) 2 (7%)
Calcium-blockers 23 (33%) 5 (16%)
ACE-/AT-II-inhibitors 22 (31%) 17 (55%)
Diuretics 27 (39%) 11 (36%)
Statins 40 (57%) 19 (61%)
Data are presented as mean ± SD or n (frequency %). *p < 0.01 and †
p < 0.001 compared with Group 1. Measurement of brain natriuretic peptide
was not obtained in 3 and 1 patients in Group 1 and 2, respectively. NYHA
= New York Heart Association. Sa = Peak systolic velocity (Color tissue
Doppler). E/e′ = Peak early mitral inflow velocity/early diastolic mitral annulus
velocity (Pulsed tissue Doppler).
Group 1. Normal CPX results. Peak VO2 ≥ 83% of that predicted and peak
O2pulse ≥95% of that predicted.
Group 2. Abnormal CPX results judged not likely caused by aortic ste-
nosis. 1) Peak VO2 < 83% of that predicted and one of the following: a) normal
peak O2pulse defined as >95% of that predicted, b) low effort (respiratory
coefficient <1), c) pulmonary disease with forced expiratory volume in first
second to forced vital capacity ratio < 70% of that predicted, low breath-
ing reserve, high VE/VCO2, and normal O2pulse trajectory—or 2) Peak
VO2 ≥ 83% and peak O2pulse < 95% of that predicted.
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Therefore, we present data for the plasma brain natriuretic
peptide levels according to the upper level of normal, incor-
porating age and gender. The most frequently used assay had
upper levels of normal ranging from 25 pg/ml (youngest man)
to 77 pg/ml (oldest woman).
For statistical calculations, SPSS Statistics software version
20 (IBM Corp., Armonk, New York) was used. Continuous
variables are presented as their means ± SD if not otherwise
indicated. Unpaired t tests and 95% confidence intervals (CI)
were used to compare the means of 2 groups. Paired t tests
were used to determine serial changes. To calculate between-
group differences in categorical variables, Fisher’s test was
used. The 95% CI for proportions were calculated accord-
ing to Newcombe.13 The normality of the continuous variables
was secured with a Shapiro-Wilk test.
Results
Over the course of 19 months (March 1 2010 to October
1 2011), 119 patients fulfilled the study criteria and con-
sented. Eighteen patients were immediately recommended AVR
because CPET suggested a significant hemodynamic com-
promise, likely resulting from the aortic stenosis. These patients
were excluded from this study. Data for these 18 patients are
presented in the supplemental material (Tables S1 and S2).
Baseline characteristics and baseline CPET results for
the study population (n = 101) are presented in Table 1 and
Table 2, respectively. The median age in the study popula-
tion was 75 years (interquartile range 65 to 79 years). The
clinical outcomes over a mean observation time of 24 months
(ranging from 12 to 36 months) with complete follow-up are
presented in Table 3. The impact of possible predictors on
outcomes is presented in Table 4 and in the supplemental
material (Table S3).
One patient succumbed to cardiac death from progres-
sive heart failure 17 months after the baseline CPET, but this
patient had been recommended AVR for the first time 8 months
earlier and again 4 months earlier during hospitalization with
heart failure. Among the patients who were hospitalized for
heart failure, 2 (both from group 2) had been recommended
for AVR earlier during the study. However, both patients had
declined the operation. In group 1, hospitalizations with heart
failure were triggered by new dysregulated atrial fibrillation
in 2 patients and by an anterior ST elevation myocardial in-
farction in 1 other patient. The all-cause mortality of 4.0%
(95% CI 1.6% to 9.7%) at a mean 2-year follow-up was not
Table 2
Cardiopulmonary exercise test results in the two groups
Group 1
(n = 70)
Group 2
(n = 31)
Peak VO2 (mL/min/kg) 22.0 ± 6.0 16.5 ± 3.7†
Peak VO2 (% of predicted) 110 ± 18 78 ± 12†
Peak O2pulse (mL O2 per beat) 12.7 ± 3.3 11.0 ± 3.0
Peak O2pulse (% of predicted) 120 ± 19 94 ± 21†
% of predicted peak heart rate 89 ± 11 83 ± 14
Respiratory coefficient 1.07 ± 0.10 1.03 ± 0.09
Anaerobic threshold (at % of predicted
peak VO2)
71 ± 14 51 ± 9†
VE/VCO2 30 ± 3 33 ± 6*
% of predicted forced expiratory volume
first second
103 ± 30 84 ± 25†
Breathing Reserve 43 ± 20 45 ± 21
Stroke volume index resting (mL/m2) 34 ± 9 29 ± 8*
Stroke volume index submaximal
exercise (mL/m2)
43 ± 9 36 ± 9*
PeakO2pulse/Hemoglobin index (mL/m2) 47 ± 8 40 ± 9†
Systolic blood pressure increase < 20 mm Hg 21 (30%) 8 (26%)
Symptoms during exercise test 3 (4%) 9 (29%)†
Valvuloarterial impedance 5.5 ± 1.7 6.1 ± 1.5
Data are presented as mean ± SD or n (%). * p < 0.01, † p < 0.001 com-
pared with Group 1.
VO2 = Oxygen consumption; O2pulse = Oxygen pulse (VO2/heart rate);
VE/VCO2 = Ventilation/Carbon dioxide exhaustion at nadir; Valvuloarterial
impedance = (Systolic blood pressure + mean gradient)/Stroke volume index
at rest. Stroke volume index measured by inert gas rebreathing.
Table 3
Clinical outcome
All study
patients
(n = 101)
Group 1
(n = 70)
Group 2
(n = 31)
Unexpected cardiac death 0 0 0
Unexpected hospitalization with
heart failure
6 (6%) 6 (9%) 0
Cardiac death, hospitalization with
heart failure or aortic valve
replacement
38 (38%) 26 (37%) 12 (39%)
Deaths of all causes 4 (4%) 1 (1.4%) 3 (10%)
Cardiac death 1 (1%) 0 1 (3%)
Hospitalization with heart failure 8 (8%) 6 (9%) 2 (7%)
Cardiac death or hospitalization
with heart failure
8 (8%) 6 (9%) 2 (7%)
Aortic valve replacement 36 (36%) 25 (36%) 11 (36%)
Data are presented as n (%).
Unexpected events: Events in patients not recommended aortic valve re-
placement earlier during the study. There were no sudden deaths.
Table 4
Odds ratios for possible predictors of outcome
Cardiac death or
Hospitalized with
heart failure
Odds ratio
(95% confidence
interval)
Cardiac death
Hospitalized with
heart failure or
aortic valve
replacement
Odds ratio
(95% confidence
interval)
Equivocally/mildly symptomatic 0.5 (0.1–2.0) 1.0 (0.4–2.3)
NYHA class II or III 0.73 (0.2–3.2) 0.4 (0.2–1.0)*
Brain natriuretic peptide > ULN 3.5 (0.8–15) 1.8 (0.7–4.7)
Symptoms during exercise test -† 0.5 (0.1–2.0)
Increase in SBP < 20 mm Hg 0.8 (0.2–4.3) 1.0 (0.4–2.5)
ST-depression ≥ 2 mm -† 0.91 (0.4–2.3)
Respiratory coefficient < 1 0.5 (0.1-4-0) 0.7 (0.2–2.0)
* P = 0.04 for worse outcome in NYHA class I.
† No patients with symptoms or ST-depression during exercise test suf-
fered cardiac death or hospitalization with heart failure.
ULN = Upper level of normal according to age and gender; SBP = Sys-
tolic blood pressure.
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higher than that of the age- and gender-matched population
in our region. This was 4.0% per year,5 amounting to 8% over
2 years. A table describing the age and gender distributions
of the study population is provided in the supplemental ma-
terial (Table S4). Causes of death included progressive heart
failure (n = 1), ileus (n = 1), pancreatitis secondary to gall-
stones (n = 1), and alcoholic hepatitis (n = 1). The 30-day and
1-year mortality rates among the 582 non–high-risk pa-
tients who underwent single AVR in our country and were
reported to the Danish Heart Register in 2012 were 1.5% and
5.3%, respectively.5
The mean time interval from baseline CPET to clinical pro-
gression leading to AVR was 18 ± 6 and 14 ± 7 months in
groups 1 and 2, respectively. AVR was performed at a mean
of 2.0 ± 1.5 months thereafter. The clinical progression leading
to AVR included the following: hospitalization with heart
failure (n = 6), new or progressing exercise-induced symp-
toms (dyspnea or syncope) or decreasing threshold for
symptoms (n = 25), new atrial fibrillation and progression in
dyspnea (n = 2), angina pectoris or acute coronary syn-
drome (n = 2), and progressive worsening of CPET results
in an asymptomatic patient with very severe aortic stenosis
(n = 1). Surgical AVR, surgical AVR with coronary artery
bypass, and transfemoral AVR were performed in 21, 11, and
4 patients, respectively. Transfemoral AVR was not per-
formed for clinical reasons, but as part of a randomized study
of patients older than 70 years eligible for surgical AVR that
showed neutral outcome.14
Serial measurements of peak VO2 at baseline, pre-AVR
(“symptomatic state”), and 9 months post-AVR were avail-
able for 23 of 25 patients in group 1 and for 9 of 11 patients
in group 2 (Figure 1). Serial echocardiographic data were avail-
able in 22 of 25 patients and 8 of 11 patients in groups 1 and
2, respectively: From immediately preoperatively (symptom-
atic state) to 9 months postoperatively, Sa increased from
4.8 ± 1.1 cm/s to 5.5 ± 1.4 cm/s (95% CI for an increase 0.22
to 1.12 cm/s, p = 0.006) in group 1 and from 4.2 ± 1.2 cm/s
to 5.1 ± 0.74 cm/s (95% CI for an increase −0.34 to 2.01 cm/s,
p = 0.13) in group 2. The E/e′ decreased from 17.6 ± 7.0 to
13.3 ± 5.4 (95% CI for a decrease −7.3 to −1.4 cm/s, p = 0.006)
in group 1 and 14.4 ± 5.3 to 13.6 ± 5.3 (95% CI for a de-
crease −5.87 to 4.13 cm/s, p = 0.68) in group 2. Among the
patients who had AVR and a plasma brain natriuretic peptide
measurement obtained at baseline and post-AVR, the number
of patients with a value greater than the upper level of normal
was 11 of 32 at baseline and 13 of 32 post-AVR.
Discussion
According to our predefined criteria, we found that if CPET
did not indicate significant hemodynamic compromise re-
sulting from aortic stenosis, an initially conservative treatment
strategy had a good prognosis for subsequent years with no
unexpected cardiac deaths. Patient survival rate was compa-
rable with the age- and gender-matched population, and only
35% of patients required an AVR during a mean follow-up
period of 2 years.
A normal CPET (group 1) did not prevent unexpected hos-
pitalization with heart failure, and the rate of hospitalization
with heart failure or AVR was similar to group 2. Obviously,
a peak VO2 of 90% of the predicted is abnormal if the pa-
tient’s normal peak VO2 was 120%. However, we do not
think that a patient with such a decrease would be regarded
as asymptomatic or questionably symptomatic by a cardi-
ologist. Thus, they would not represent the typical patient
included in our study. Mortality was low in group 1, which
is unsurprising because of the close relation between peak
VO2 and survival. Significant improvements in peak VO2 after
AVR were observed, suggesting the valve disease was a major
cause of symptoms in those who progressed to AVR in this
group.
Patients in group 2 had subnormal values of peak VO2 and/
or peak O2pulse. Thus, they displayed objectively decreased
exercise capacity. Furthermore, 84% had some symptoms in
Figure 1. Serial measurements of the mean peak VO2 as a percentage of that predicted for patients who had aortic valve replacements in the 2 groups. Bars = stan-
dard deviation. In group 1 (n = 23), the 95% CI for an increase from just pre-AVR to 9 months post-AVR was 0.0% to 7.9% (p = 0.050). In group 2 (n = 9),
the 95% CI for a decrease was −12.4% to −0.62% (p = 0.034). A relative increase in peak VO2 >5% from symptomatic pre-AVR to post-AVR, which corre-
sponds to the coefficient of reproducibility in patients with aortic stenosis,7 was observed in 11 of 23 in group 1 and in 2 of 9 in group 2.
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daily life, and 68% were deemed New York Heart Associa-
tion functional class II. Therefore, a physician could have
referred nearly all of these patients for AVR because of severe
aortic stenosis and symptoms or decreased exercise capac-
ity. Nevertheless, the rate of unexpected cardiac death or
hospitalization with heart failure was 0% in group 2. For pa-
tients in group 2 who had an AVR, improvements in peak VO2
were not observed. Because Sa and E/e′ tended to improve,
this suggest that the timing of AVR was not overdue. The low
peak VO2 and lack of improvements in peak VO2 suggest that
causes other than the valve disease were the major reasons
for symptoms and low functional capacity. The mean gradi-
ent was low compared with the aortic valve area index,
although the mean Sa and left ventricular ejection fraction
values were comparable with those in group 1. This is well
explained by the resting stroke volume that was clearly lower,
as assessed by inert gas rebreathing (Table 1). A lower resting
stroke volume is a key finding in unfit subjects with normal
left ventricular ejection fraction.15 The mortality in this group
was 9.9%. Although there is uncertainty because of the low
n, this is acceptable compared with the expected 8% in the
age- and gender-matched population because of the high rate
of co-morbidities.
How does this study expand upon previous studies? Das
et al1 found that field exercise testing was not useful in pa-
tients >70 years or in those deemed functional class II. Patients
with co-morbidities,1,16 symptoms during the test16,17—a sub-
jective criterion,2 or a low exercise capacity17 were excluded
in many studies. However, patients with aortic stenosis are
often older. They also tend to have co-morbidities and symp-
toms that are difficult to assess. It is for these patients that
decisions regarding treatment strategies are difficult and am-
biguous. Our study suggests that CPET is useful in such patient
groups. This included patients with revealed symptoms, ST
depression >2 mm, decreased blood pressure response during
exercise test, low exercise capacity, respiratory coeffi-
cient <1, or brain natriuretic peptide greater than the upper
level of normal. In a cohort with a mean age of 64 years and
53% (n = 71) with an aortic valve area <1 cm2/m2, Marechaux
et al16 found an event rate of cardiac death, heart failure, or
AVR of 50% after a mean follow-up of 20 months after a
normal field exercise test result, that is, a negative predic-
tive value of 50%. In the older population in our study, all
of them had an aortic valve area index <0.6 cm2/m2, and the
event rate at a mean follow-up of 24 months was 37%. This
presents a negative predictive value for a CPET without sug-
gesting a significant hemodynamic compromise of 63%. In
a meta-analysis that included 491 largely asymptomatic pa-
tients with a mean age of 62 years and a mean aortic valve
area index of 0.47 cm2/m2, the rate of cardiac death or symp-
toms leading to AVR was 42% at a mean follow-up of 14
months.18 These observations suggest that a CPET-guided strat-
egy may lead to a lower event rate (higher negative predictive
value) than that obtained using a field exercise test strategy
without sacrificing safety.
Our study had some limitations. Only a few patients in our
cohort (9%) had very severe aortic stenosis with peak gra-
dients >100 mm Hg.7 However, only in cases when the
cardiologist judges the patient asymptomatic or equivocally
symptomatic for severe or borderline to severe aortic steno-
sis is assessment ambiguous, requiring additional diagnostic
information. Furthermore, patients who were not able to
perform an exercise test were not referred or included.
However, such frail patients are seldom considered for AVR
if they are only asymptomatic or questionably symptom-
atic. No randomization against field exercise testing was done.
However, the limitations of field exercise testing in patients
aged >70 years with co-morbidities or with some symp-
toms or functional limitation are well-recognized.1 Therefore,
we feel that our finding that a CPET-guided strategy was fol-
lowed by a good prognosis and an acceptable event rate, in
such patients who are difficult to assess, provides new and
useful information. To compare mortality with that in the back-
ground population would ideally also demand a match in peak
VO2, because some patients can be supervariants with aortic
stenosis. Obviously, this is a nearly impossible task. The cause
of death and hospitalizations for heart failure was not deter-
mined by an independent assessment committee. However,
all deaths occurred in the hospital at other institutions, and
the cause of death was determined by local physicians and
stated in the discharge summary.
In conclusion, we examined a study population with a
median age of 75 years that displayed echocardiographically
severe aortic stenosis, including two-thirds who had some
symptoms. If CPET did not indicate primary significant he-
modynamic compromise from the aortic stenosis, we found
that an initially conservative treatment strategy was associ-
ated with a good prognosis and an acceptable rate of cardiac
events.
Disclosures
The authors have no conflicts of interest to disclose.
Supplementary Data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.amjcard.2017.05.047.
1. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic
stenosis. Eur Heart J 2005;26:1309–1313.
2. Bonow RO. Exercise hemodynamics and risk assessment in asymp-
tomatic aortic stenosis. Circulation 2012;126:803–805.
3. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G,
Baumgartner H, Borger MA, Carrel TP, DeBonis M, Evangelista A, Falk
V, Iung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G,
Stepinska J, Swedberg K, Takkenberg J, von Oppell UO, Windecker S,
Zamorano JL, Zembala M. Guidelines on the management of valvular
heart disease. Eur Heart J 2012;33:2451–2496.
4. Wasserman K. Diagnosing cardiovascular and lung pathophysiology from
exercise gas exchange. Chest 1997;112:1091–1101.
5. Danish Heart Registry. Yearly report 2012. Available at: http://www.si-
folkesundhed.dk/upload/dhr_%C3%A5rsberetning_2012.pdf, pp 135–
150. Accessed on July 5, 2017.
6. Statistics Denmark. Death by region, age and sex. Available at: http://
www.statbank.dk/FOD507. Accessed on July 5, 2017.
7. Van Le D, Jensen GVJ, Carstensen S, Kjøller-Hansen L. Cardiopulmo-
nary exercise testing in asymptomatic or equivocal symptomatic aortic
stenosis. Feasibility, reproducibility, safety and information obtained on
exercise physiology. Cardiology 2016;133:147–156.
8. Agostoni PG, Wasserman K, Perego GB, Guazzi M, Cattadori G, Palermo
P, Lauri G, Marenzi G. Non-invasive measurement of stroke volume
during exercise in heart failure patients. Clin Sci 2000;98:545–551.
9. Wasserman K, Hansen EJ, Sue YD, Stringer WW, Whipp BJ. Prin-
ciples of Exercise Testing and Interpretation: Including Pathophysiology
and Clinical Applications. 4th ed. Philadelphia, PA: Lippincott, Williams
and Wilkins; 2005 pages 69, 146, 173 and 217.
848 The American Journal of Cardiology (www.ajconline.org)
10. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhess L,
Arena R, Fletcher GF, Forman DE, Kitzman DW, Lawie CJ, Myers J.
European Association for Cardiovascular Prevention & Rehabilitation;
American Heart Association. EACPR/AHA Scientific Statement Clinical
Recommendations for Cardiopulmonary Exercise Testing Data Assess-
ment in Specific Patient Populations. Circulation 2012;126:2261–2274.
11. Sue DY, Hansen JE. Normal values in adults during exercise testing.
Clin Chest Med 1984;5:89–98.
12. Bruch C, Stypmann J, Grude M, Gradaus R, Breithardt G, Wichter T.
Tissue Doppler imaging in patients with moderate to severe aortic valve
stenosis: clinical usefulness and diagnostic accuracy. Am Heart J
2004;148:696–702.
13. Newcombe RG. Two-sided confidence intervals for the single propor-
tion: comparison of seven methods. Stat Med 1998;17:857–872.
14. Thyregod HCH, Steinbrüchel DA, Ihlemann N, Nissen H, Kjeldsen BJ,
Peursson P, Chang Y, Franzen OF, Engstrøm T, Clemmensen P, Hansen
PB, Andersen LW, Olsen PS, Søndergaard L. Transcatheter versus
surgical valve replacement in patients with severe aortic valve steno-
sis. J Am Coll Cardiol 2015;65:2184–2194.
15. Saltin B, Calbet JA. In health and in a normoxic environment, VO2 max
is limited primarily by cardiac output and locomotor muscle blood flow.
J Appl Physiol 2006;100:744–748.
16. Marechaux S, Hachicha Z, Bellouin A, Dumesnil JG, Meimoun P, Pasquet
A, Bergeron S, Arsenault A, Tourneau TL, Ennezat PV, Pibarot P. Use-
fulness of exercise-stress echocardiography for risk stratification of true
asymptomatic patients with aortic valve stenosis. Eur Heart J
2010;31:1390–1397.
17. Lancellotti P, Magne J, Donal E, O’Connor K, Dulgheru R, Rosca M,
Pierard LA. Determinants and prognostic significance of exercise pul-
monary hypertension in asymptomatic severe aortic stenosis. Circulation
2012;126:851–859.
18. Rafique AM, Biner S, Ray I, Forrester JS, Tolstrup K, Siegel RJ. Meta-
analysis of prognostic value of stress testing in patients with asymptomatic
severe aortic stenosis. Am J Cardiol 2009;104:972–977.
849Valvular Heart Disease/A CPET-Guided Strategy for Aortic Stenosis
